APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Intravenous (IV) Iron Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Intravenous (IV) Iron Drugs Market Outlook and Growth Opportunities 2026

Report ID 174004310426 December 2025190 pages

Choose your research edition.

Industry ResearchIntravenous (IV) Iron Drugs Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Intravenous (IV) Iron Drugs Industry Growth and Trends Forecast to 203299 pages · $3,450 USDMarket StructureGlobal Intravenous (IV) Iron Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Intravenous (IV) Iron Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Intravenous (IV) Iron Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Intravenous (IV) Iron Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Intravenous (IV) Iron Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Intravenous (IV) Iron Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Intravenous (IV) Iron Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Intravenous (IV) Iron Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Intravenous (IV) Iron Drugs market include Takeda Pharmaceutical, Sanofi US, Pharmacosmos, Luitpold Pharmaceuticals, Dalichi Sankyo, AMAG Pharmaceuticals and Allergan, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Intravenous (IV) Iron Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Intravenous (IV) Iron Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Intravenous (IV) Iron Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Intravenous (IV) Iron Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Intravenous (IV) Iron Drugs Segment by Company

Takeda Pharmaceutical

Sanofi US

Pharmacosmos

Luitpold Pharmaceuticals

Dalichi Sankyo

AMAG Pharmaceuticals

Allergan

Intravenous (IV) Iron Drugs Segment by Type

Ferric Carboxymaltose

Iron Dextran

Iron Sucrose

Others

Intravenous (IV) Iron Drugs Segment by Application

Gynecology & Obstetrics

Nephrology

Gastroenterology

Cardiology

Oncology

Others

Intravenous (IV) Iron Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Intravenous (IV) Iron Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Intravenous (IV) Iron Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Intravenous (IV) Iron Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Intravenous (IV) Iron Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Intravenous (IV) Iron Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Intravenous (IV) Iron Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Intravenous (IV) Iron Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Intravenous (IV) Iron Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Intravenous (IV) Iron Drugs industry.

Chapter 3: Detailed analysis of Intravenous (IV) Iron Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Intravenous (IV) Iron Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Intravenous (IV) Iron Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Intravenous (IV) Iron Drugs Industry Trends Table 2. Intravenous (IV) Iron Drugs Industry Drivers Table 3. Intravenous (IV) Iron Drugs Industry Opportunities and Challenges Table 4. Intravenous (IV) Iron Drugs Industry Restraints Table 5. Global Intravenous (IV) Iron Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Intravenous (IV) Iron Drugs Revenue Share by Company (2021-2026) Table 7. Global Intravenous (IV) Iron Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Intravenous (IV) Iron Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Intravenous (IV) Iron Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Intravenous (IV) Iron Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Intravenous (IV) Iron Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Intravenous (IV) Iron Drugs Company, Product Type & Application Table 13. Global Intravenous (IV) Iron Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Intravenous (IV) Iron Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Ferric Carboxymaltose Table 18. Significant Companies of Iron Dextran Table 19. Significant Companies of Iron Sucrose Table 20. Significant Companies of Others Table 21. Global Intravenous (IV) Iron Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Intravenous (IV) Iron Drugs Sales Volume by Type (2021-2026) & (K Units) Table 23. Global Intravenous (IV) Iron Drugs Sales Volume by Type (2027-2032) & (K Units) Table 24. Global Intravenous (IV) Iron Drugs Sales Volume Share by Type (2021-2026) Table 25. Global Intravenous (IV) Iron Drugs Sales Volume Share by Type (2027-2032) Table 26. Global Intravenous (IV) Iron Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Intravenous (IV) Iron Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Intravenous (IV) Iron Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Intravenous (IV) Iron Drugs Sales Value Share by Type (2021-2026) Table 30. Global Intravenous (IV) Iron Drugs Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Gynecology & Obstetrics Table 32. Significant Companies of Nephrology Table 33. Significant Companies of Gastroenterology Table 34. Significant Companies of Cardiology Table 35. Significant Companies of Oncology Table 36. Significant Companies of Others Table 37. Global Intravenous (IV) Iron Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Intravenous (IV) Iron Drugs Sales Volume by Application (2021-2026) & (K Units) Table 39. Global Intravenous (IV) Iron Drugs Sales Volume by Application (2027-2032) & (K Units) Table 40. Global Intravenous (IV) Iron Drugs Sales Volume Share by Application (2021-2026) Table 41. Global Intravenous (IV) Iron Drugs Sales Volume Share by Application (2027-2032) Table 42. Global Intravenous (IV) Iron Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global Intravenous (IV) Iron Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global Intravenous (IV) Iron Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global Intravenous (IV) Iron Drugs Sales Value Share by Application (2021-2026) Table 46. Global Intravenous (IV) Iron Drugs Sales Value Share by Application (2027-2032) Table 47. Global Intravenous (IV) Iron Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 48. Global Intravenous (IV) Iron Drugs Sales by Region (2021-2026) & (K Units) Table 49. Global Intravenous (IV) Iron Drugs Sales Market Share by Region (2021-2026) Table 50. Global Intravenous (IV) Iron Drugs Sales by Region (2027-2032) & (K Units) Table 51. Global Intravenous (IV) Iron Drugs Sales Market Share by Region (2027-2032) Table 52. Global Intravenous (IV) Iron Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global Intravenous (IV) Iron Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global Intravenous (IV) Iron Drugs Sales Value Share by Region (2021-2026) Table 55. Global Intravenous (IV) Iron Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global Intravenous (IV) Iron Drugs Sales Value Share by Region (2027-2032) Table 57. Global Intravenous (IV) Iron Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global Intravenous (IV) Iron Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global Intravenous (IV) Iron Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. Global Intravenous (IV) Iron Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Intravenous (IV) Iron Drugs Sales by Country (2021-2026) & (K Units) Table 62. Global Intravenous (IV) Iron Drugs Sales Market Share by Country (2021-2026) Table 63. Global Intravenous (IV) Iron Drugs Sales by Country (2027-2032) & (K Units) Table 64. Global Intravenous (IV) Iron Drugs Sales Market Share by Country (2027-2032) Table 65. Global Intravenous (IV) Iron Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global Intravenous (IV) Iron Drugs Sales Value Market Share by Country (2021-2026) Table 67. Global Intravenous (IV) Iron Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global Intravenous (IV) Iron Drugs Sales Value Market Share by Country (2027-2032) Table 69. Takeda Pharmaceutical Company Information Table 70. Takeda Pharmaceutical Business Overview Table 71. Takeda Pharmaceutical Intravenous (IV) Iron Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Takeda Pharmaceutical Intravenous (IV) Iron Drugs Product Portfolio Table 73. Takeda Pharmaceutical Recent Development Table 74. Sanofi US Company Information Table 75. Sanofi US Business Overview Table 76. Sanofi US Intravenous (IV) Iron Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Sanofi US Intravenous (IV) Iron Drugs Product Portfolio Table 78. Sanofi US Recent Development Table 79. Pharmacosmos Company Information Table 80. Pharmacosmos Business Overview Table 81. Pharmacosmos Intravenous (IV) Iron Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Pharmacosmos Intravenous (IV) Iron Drugs Product Portfolio Table 83. Pharmacosmos Recent Development Table 84. Luitpold Pharmaceuticals Company Information Table 85. Luitpold Pharmaceuticals Business Overview Table 86. Luitpold Pharmaceuticals Intravenous (IV) Iron Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Luitpold Pharmaceuticals Intravenous (IV) Iron Drugs Product Portfolio Table 88. Luitpold Pharmaceuticals Recent Development Table 89. Dalichi Sankyo Company Information Table 90. Dalichi Sankyo Business Overview Table 91. Dalichi Sankyo Intravenous (IV) Iron Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Dalichi Sankyo Intravenous (IV) Iron Drugs Product Portfolio Table 93. Dalichi Sankyo Recent Development Table 94. AMAG Pharmaceuticals Company Information Table 95. AMAG Pharmaceuticals Business Overview Table 96. AMAG Pharmaceuticals Intravenous (IV) Iron Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. AMAG Pharmaceuticals Intravenous (IV) Iron Drugs Product Portfolio Table 98. AMAG Pharmaceuticals Recent Development Table 99. Allergan Company Information Table 100. Allergan Business Overview Table 101. Allergan Intravenous (IV) Iron Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Allergan Intravenous (IV) Iron Drugs Product Portfolio Table 103. Allergan Recent Development Table 104. Key Raw Materials Table 105. Raw Materials Key Suppliers Table 106. Intravenous (IV) Iron Drugs Distributors List Table 107. Intravenous (IV) Iron Drugs Customers List Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Intravenous (IV) Iron Drugs Product Image Figure 2. Global Intravenous (IV) Iron Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Intravenous (IV) Iron Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Intravenous (IV) Iron Drugs Sales (2021-2032) & (K Units) Figure 5. Global Intravenous (IV) Iron Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Intravenous (IV) Iron Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Ferric Carboxymaltose Image Figure 10. Iron Dextran Image Figure 11. Iron Sucrose Image Figure 12. Others Image Figure 13. Global Intravenous (IV) Iron Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Intravenous (IV) Iron Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Intravenous (IV) Iron Drugs Sales Volume Share by Type (2021-2032) Figure 16. Global Intravenous (IV) Iron Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Intravenous (IV) Iron Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Intravenous (IV) Iron Drugs Sales Value Share by Type (2021-2032) Figure 19. Gynecology & Obstetrics Image Figure 20. Nephrology Image Figure 21. Gastroenterology Image Figure 22. Cardiology Image Figure 23. Oncology Image Figure 24. Others Image Figure 25. Global Intravenous (IV) Iron Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Intravenous (IV) Iron Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global Intravenous (IV) Iron Drugs Sales Volume Share by Application (2021-2032) Figure 28. Global Intravenous (IV) Iron Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global Intravenous (IV) Iron Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global Intravenous (IV) Iron Drugs Sales Value Share by Application (2021-2032) Figure 31. Global Intravenous (IV) Iron Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 32. Global Intravenous (IV) Iron Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global Intravenous (IV) Iron Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global Intravenous (IV) Iron Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America Intravenous (IV) Iron Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. North America Intravenous (IV) Iron Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe Intravenous (IV) Iron Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. Europe Intravenous (IV) Iron Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific Intravenous (IV) Iron Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific Intravenous (IV) Iron Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America Intravenous (IV) Iron Drugs Sales Value (2021-2032) & (US$ Million) Figure 42. South America Intravenous (IV) Iron Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa Intravenous (IV) Iron Drugs Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa Intravenous (IV) Iron Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. Intravenous (IV) Iron Drugs Value Chain Figure 130. Manufacturing Cost Structure Figure 131. Intravenous (IV) Iron Drugs Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • Ferric Carboxymaltose
  • Iron Dextran
  • Iron Sucrose
  • Others
Applications
  • Gynecology & Obstetrics
  • Nephrology
  • Gastroenterology
  • Cardiology
  • Oncology
  • Others
Companies covered
  • Takeda Pharmaceutical
  • Sanofi US
  • Pharmacosmos
  • Luitpold Pharmaceuticals
  • Dalichi Sankyo
  • AMAG Pharmaceuticals
  • Allergan

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Intravenous (IV) Iron Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Intravenous (IV) Iron Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Intravenous (IV) Iron Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Intravenous (IV) Iron Drugs Market Dynamics
  1. 2.1 Intravenous (IV) Iron Drugs Industry Trends
  2. 2.2 Intravenous (IV) Iron Drugs Industry Drivers
  3. 2.3 Intravenous (IV) Iron Drugs Industry Opportunities and Challenges
  4. 2.4 Intravenous (IV) Iron Drugs Industry Restraints
3 Intravenous (IV) Iron Drugs Market by Company
  1. 3.1 Global Intravenous (IV) Iron Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Intravenous (IV) Iron Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Intravenous (IV) Iron Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Intravenous (IV) Iron Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Intravenous (IV) Iron Drugs Company Ranking (2024-2026)
  6. 3.6 Global Intravenous (IV) Iron Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Intravenous (IV) Iron Drugs Company Product Type and Application
  8. 3.8 Global Intravenous (IV) Iron Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Intravenous (IV) Iron Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Intravenous (IV) Iron Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Intravenous (IV) Iron Drugs Market by Type
  1. 4.1 Intravenous (IV) Iron Drugs Type Introduction
  2. 4.1.1 Ferric Carboxymaltose
  3. 4.1.2 Iron Dextran
  4. 4.1.3 Iron Sucrose
  5. 4.1.4 Others
  6. 4.2 Global Intravenous (IV) Iron Drugs Sales Volume by Type
  7. 4.2.1 Global Intravenous (IV) Iron Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Intravenous (IV) Iron Drugs Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Intravenous (IV) Iron Drugs Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Intravenous (IV) Iron Drugs Sales Value by Type
  11. 4.3.1 Global Intravenous (IV) Iron Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Intravenous (IV) Iron Drugs Sales Value by Type (2021-2032)
  13. 4.3.3 Global Intravenous (IV) Iron Drugs Sales Value Share by Type (2021-2032)
5 Intravenous (IV) Iron Drugs Market by Application
  1. 5.1 Intravenous (IV) Iron Drugs Application Introduction
  2. 5.1.1 Gynecology & Obstetrics
  3. 5.1.2 Nephrology
  4. 5.1.3 Gastroenterology
  5. 5.1.4 Cardiology
  6. 5.1.5 Oncology
  7. 5.1.6 Others
  8. 5.2 Global Intravenous (IV) Iron Drugs Sales Volume by Application
  9. 5.2.1 Global Intravenous (IV) Iron Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global Intravenous (IV) Iron Drugs Sales Volume by Application (2021-2032)
  11. 5.2.3 Global Intravenous (IV) Iron Drugs Sales Volume Share by Application (2021-2032)
  12. 5.3 Global Intravenous (IV) Iron Drugs Sales Value by Application
  13. 5.3.1 Global Intravenous (IV) Iron Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  14. 5.3.2 Global Intravenous (IV) Iron Drugs Sales Value by Application (2021-2032)
  15. 5.3.3 Global Intravenous (IV) Iron Drugs Sales Value Share by Application (2021-2032)
6 Intravenous (IV) Iron Drugs Regional Sales and Value Analysis
  1. 6.1 Global Intravenous (IV) Iron Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Intravenous (IV) Iron Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Intravenous (IV) Iron Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Intravenous (IV) Iron Drugs Sales by Region (2027-2032)
  5. 6.3 Global Intravenous (IV) Iron Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Intravenous (IV) Iron Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Intravenous (IV) Iron Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Intravenous (IV) Iron Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Intravenous (IV) Iron Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Intravenous (IV) Iron Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Intravenous (IV) Iron Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Intravenous (IV) Iron Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Intravenous (IV) Iron Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Intravenous (IV) Iron Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Intravenous (IV) Iron Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Intravenous (IV) Iron Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Intravenous (IV) Iron Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Intravenous (IV) Iron Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Intravenous (IV) Iron Drugs Sales Value Share by Country, 2025 VS 2032
7 Intravenous (IV) Iron Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Intravenous (IV) Iron Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Intravenous (IV) Iron Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Intravenous (IV) Iron Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Intravenous (IV) Iron Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Intravenous (IV) Iron Drugs Sales by Country (2027-2032)
  6. 7.4 Global Intravenous (IV) Iron Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Intravenous (IV) Iron Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Intravenous (IV) Iron Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Intravenous (IV) Iron Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Intravenous (IV) Iron Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Intravenous (IV) Iron Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical
  2. 8.1.1 Takeda Pharmaceutical Company Information
  3. 8.1.2 Takeda Pharmaceutical Business Overview
  4. 8.1.3 Takeda Pharmaceutical Intravenous (IV) Iron Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Intravenous (IV) Iron Drugs Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Recent Developments
  7. 8.2 Sanofi US
  8. 8.2.1 Sanofi US Company Information
  9. 8.2.2 Sanofi US Business Overview
  10. 8.2.3 Sanofi US Intravenous (IV) Iron Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi US Intravenous (IV) Iron Drugs Product Portfolio
  12. 8.2.5 Sanofi US Recent Developments
  13. 8.3 Pharmacosmos
  14. 8.3.1 Pharmacosmos Company Information
  15. 8.3.2 Pharmacosmos Business Overview
  16. 8.3.3 Pharmacosmos Intravenous (IV) Iron Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Pharmacosmos Intravenous (IV) Iron Drugs Product Portfolio
  18. 8.3.5 Pharmacosmos Recent Developments
  19. 8.4 Luitpold Pharmaceuticals
  20. 8.4.1 Luitpold Pharmaceuticals Company Information
  21. 8.4.2 Luitpold Pharmaceuticals Business Overview
  22. 8.4.3 Luitpold Pharmaceuticals Intravenous (IV) Iron Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Luitpold Pharmaceuticals Intravenous (IV) Iron Drugs Product Portfolio
  24. 8.4.5 Luitpold Pharmaceuticals Recent Developments
  25. 8.5 Dalichi Sankyo
  26. 8.5.1 Dalichi Sankyo Company Information
  27. 8.5.2 Dalichi Sankyo Business Overview
  28. 8.5.3 Dalichi Sankyo Intravenous (IV) Iron Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Dalichi Sankyo Intravenous (IV) Iron Drugs Product Portfolio
  30. 8.5.5 Dalichi Sankyo Recent Developments
  31. 8.6 AMAG Pharmaceuticals
  32. 8.6.1 AMAG Pharmaceuticals Company Information
  33. 8.6.2 AMAG Pharmaceuticals Business Overview
  34. 8.6.3 AMAG Pharmaceuticals Intravenous (IV) Iron Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 AMAG Pharmaceuticals Intravenous (IV) Iron Drugs Product Portfolio
  36. 8.6.5 AMAG Pharmaceuticals Recent Developments
  37. 8.7 Allergan
  38. 8.7.1 Allergan Company Information
  39. 8.7.2 Allergan Business Overview
  40. 8.7.3 Allergan Intravenous (IV) Iron Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Allergan Intravenous (IV) Iron Drugs Product Portfolio
  42. 8.7.5 Allergan Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Intravenous (IV) Iron Drugs Value Chain Analysis
  2. 9.1.1 Intravenous (IV) Iron Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Intravenous (IV) Iron Drugs Sales Mode & Process
  6. 9.2 Intravenous (IV) Iron Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Intravenous (IV) Iron Drugs Distributors
  9. 9.2.3 Intravenous (IV) Iron Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst